Collaboration agreement with Intuitive

Creo technology to be adapted for use with robotic-assisted surgical platform

Creo Medical Group plc, a medical device company focused on the emerging field of surgical endoscopy, is pleased to announce that it has signed a long-term, multi-year collaboration agreement with Intuitive to optimise certain Creo products to be compatible with Intuitive’s robotic technology. Intuitive (Nasdaq: ISRG) is a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery.

Along with the optimisation of Creo’s products, the Agreement provides a framework to allow joint clinical studies to be undertaken and includes a number of milestone payments to be made to Creo. Future royalty structures have also been agreed for any products which may be sold in the future.

Creo is developing and commercialising a suite of electrosurgical medical devices, each enabled by the CROMA Advanced Energy platform and powered by Kamaptive, full-spectrum adaptive technology to help support surgical capability and patient outcomes.

Craig Gulliford, Chief Executive Officer of Creo, commented:

We are delighted to announce this exciting collaboration with Intuitive. The combination of Intuitive’s robotic platforms and our Kamaptive Technology strives to provide patients with additional treatment options using state-of-the-art technology. The collaboration highlights the versatility of Creo’s technology whilst validating the hard work that has been undertaken by Creo’s engineering team to bring advanced energy to the field of surgical endoscopy.

Technological advancements are facilitating a paradigm shift in the way many surgical procedures are delivered and we look forward to working together to enable additional options for patients using this combined state-of-the-art technology. As well as exploring technical compatibility, our teams have agreed on commercialisation terms, including clinical and regulatory fundamentals in an open and collaborative environment, to establish what we hope to be a long-lasting collaboration centred around shared goals of using thoughtfully developed technology to help improve patient outcomes.

About Kamaptive Technology

Creo is developing and commercialising a suite of electrosurgical medical devices, each enabled by the CROMA Advanced Energy platform, powered by Kamaptive. The Group has developed the Kamaptive powered full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions.

Posted 05/23/22

For press enquiries please contact For all other enquiries please visit our Contact page.

Further news

05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi


31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific


10 January 2024

First Use of Speedboat® UltraSlim in Latin America


13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch


01 November 2023

Speedboat® UltraSlim: US FDA Clearance


25 October 2023

Speedboat UltraSlim: EU launch accelerated by 18 months


12 September 2023

Half Year Report: H1-2023


19 June 2023

Speedboat Inject cleared for upper GI use in Europe


01 June 2023

Speedboat™ Inject selected by NICE for assessment


23 May 2023

First in-human milestone reached for MicroBlate™ Flex as part of Lung Tissue ablation clinical study